Cargando…

Exploiting Epigenetic Alterations in Prostate Cancer

Prostate cancer affects an increasing number of men worldwide and is a leading cause of cancer-associated deaths. Beside genetic mutations, many epigenetic alterations including DNA and histone modifications have been identified in clinical prostate tumor samples. They have been linked to aberrant a...

Descripción completa

Detalles Bibliográficos
Autores principales: Baumgart, Simon J., Haendler, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454930/
https://www.ncbi.nlm.nih.gov/pubmed/28486411
http://dx.doi.org/10.3390/ijms18051017
_version_ 1783240939450400768
author Baumgart, Simon J.
Haendler, Bernard
author_facet Baumgart, Simon J.
Haendler, Bernard
author_sort Baumgart, Simon J.
collection PubMed
description Prostate cancer affects an increasing number of men worldwide and is a leading cause of cancer-associated deaths. Beside genetic mutations, many epigenetic alterations including DNA and histone modifications have been identified in clinical prostate tumor samples. They have been linked to aberrant activity of enzymes and reader proteins involved in these epigenetic processes, leading to the search for dedicated inhibitory compounds. In the wake of encouraging anti-tumor efficacy results in preclinical models, epigenetic modulators addressing different targets are now being tested in prostate cancer patients. In addition, the assessment of microRNAs as stratification biomarkers, and early clinical trials evaluating suppressor microRNAs as potential prostate cancer treatment are being discussed.
format Online
Article
Text
id pubmed-5454930
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-54549302017-06-08 Exploiting Epigenetic Alterations in Prostate Cancer Baumgart, Simon J. Haendler, Bernard Int J Mol Sci Review Prostate cancer affects an increasing number of men worldwide and is a leading cause of cancer-associated deaths. Beside genetic mutations, many epigenetic alterations including DNA and histone modifications have been identified in clinical prostate tumor samples. They have been linked to aberrant activity of enzymes and reader proteins involved in these epigenetic processes, leading to the search for dedicated inhibitory compounds. In the wake of encouraging anti-tumor efficacy results in preclinical models, epigenetic modulators addressing different targets are now being tested in prostate cancer patients. In addition, the assessment of microRNAs as stratification biomarkers, and early clinical trials evaluating suppressor microRNAs as potential prostate cancer treatment are being discussed. MDPI 2017-05-09 /pmc/articles/PMC5454930/ /pubmed/28486411 http://dx.doi.org/10.3390/ijms18051017 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Baumgart, Simon J.
Haendler, Bernard
Exploiting Epigenetic Alterations in Prostate Cancer
title Exploiting Epigenetic Alterations in Prostate Cancer
title_full Exploiting Epigenetic Alterations in Prostate Cancer
title_fullStr Exploiting Epigenetic Alterations in Prostate Cancer
title_full_unstemmed Exploiting Epigenetic Alterations in Prostate Cancer
title_short Exploiting Epigenetic Alterations in Prostate Cancer
title_sort exploiting epigenetic alterations in prostate cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454930/
https://www.ncbi.nlm.nih.gov/pubmed/28486411
http://dx.doi.org/10.3390/ijms18051017
work_keys_str_mv AT baumgartsimonj exploitingepigeneticalterationsinprostatecancer
AT haendlerbernard exploitingepigeneticalterationsinprostatecancer